NAT2 Slow Acetylator Phenotype as a Significant Risk Factor for Hepatotoxicity Caused by Antituberculosis Drugs: Results From a Multiethnic Nested Case-Control Study
Clinical Infectious Diseases · 2025
DOI: 10.1093/cid/ciae583 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Stefania Cheli und 13 weiteren Autor:innen. Beteiligte Einrichtung: ICPS, Pharmacovigilance & Clinical Research, Department of Biomedical and Clinical Sciences, ASST Fatebenefratelli Sacco, University Hospital Luigi S…. Hauptthemen laut MEDLINE: Antitubercular Agents, Arylamine N-Acetyltransferase, Chemical and Drug Induced Liver Injury. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben.
Abstract (Originalsprache)
Background
Under standard therapies, the incidence of drug-induced liver injury (DILI) in patients with tuberculosis ranges from 2% to 28%. Numerous studies have identified the risk factors for antituberculosis DILI; however, none have been conducted in a multiethnic real-world setting. The primary outcome of the current study was to identify the risk factors that could be used as the best predictors of DILI in a multiethnic cohort.
Methods
A nested case-control study was conducted in patients at the tuberculosis clinic of Luigi Sacco Hospital in Milan.
Results
The study included 102 patients (mean age [SD], 45.6 [15.6] years). For each patient with hepatotoxicity, 2 controls were matched for sex, age, body mass index, tuberculosis/tuberculosis infection diagnosis, and index date. We found that N-acetyltransferase 2 gene (NAT2) slow acetylator status was the best independent predictor of DILI (odds ratio, 5.97 [95% confidence interval, 1.38–25.76]; P = .02].
Conclusions
NAT2 genotype–guided dosing may help optimize antituberculosis drug treatment and prevent treatment failure. Clinical Trials Registration ClinicalTrials.gov NCT06539455
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ICPS, Pharmacovigilance & Clinical Research, Department of Biomedical and Clinical Sciences, ASST Fatebenefratelli Sacco, University Hospital Luigi Sacco, Università Degli Studi di Milano, Milan, Italy.
- III Infectious Disease Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy.
- II Infectious Disease Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy.
- Center of Functional Genomics and Rare Diseases, Buzzi Children's Hospital, Milan, Italy.
- Department of Biomedical and Clinical Sciences, Università Degli Studi di Milano, Milan, Italy.
- Scientific Institute, IRCCS E. Medea, Bosisio Parini, LC, Italy.
ORCID-Profile: Stefania Cheli, Cristina Montrasio, Aurora Civati, Vera Battini, Ilaria Mariani, Giulia Mosini, Carla Carnovale, Sonia Radice, Emilio Clementi, Spinello Antinori
Zitieren
APA
Cheli, S., Torre, A., Schiuma, M., Montrasio, C., Civati, A., Galimberti, M., Battini, V., Mariani, I., Mosini, G., Carnovale, C., Radice, S., Clementi, E., Gori, A., & Antinori, S. (2025). NAT2 Slow Acetylator Phenotype as a Significant Risk Factor for Hepatotoxicity Caused by Antituberculosis Drugs: Results From a Multiethnic Nested Case-Control Study. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae583
Vancouver
Cheli S, Torre A, Schiuma M, Montrasio C, Civati A, Galimberti M, et al. NAT2 Slow Acetylator Phenotype as a Significant Risk Factor for Hepatotoxicity Caused by Antituberculosis Drugs: Results From a Multiethnic Nested Case-Control Study. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciae583
BibTeX
@article{Cheli2025,
author = {Cheli, Stefania and Torre, Alessandro and Schiuma, Marco and Montrasio, Cristina and Civati, Aurora and Galimberti, Miriam and Battini, Vera and Mariani, Ilaria and Mosini, Giulia and Carnovale, Carla and Radice, Sonia and Clementi, Emilio and Gori, Andrea and Antinori, Spinello},
title = {NAT2 Slow Acetylator Phenotype as a Significant Risk Factor for Hepatotoxicity Caused by Antituberculosis Drugs: Results From a Multiethnic Nested Case-Control Study},
journal = {Clinical Infectious Diseases},
year = {2025},
doi = {10.1093/cid/ciae583}
}
EUVIMED